Latest News

Date Title Topic
07 Nov 2016 Personalised Cancer Vaccines Cancer Immunology and Immunotherapy
Elections
02 Nov 2016 Withdrawal of the Marketing Authorisation Application for Pemetrexed (as ditromethamine) Hospira Lung and other thoracic tumours - Anticancer agents & Biologic therapy
31 Oct 2016 NICE Recommends Osimertinib for Advanced EGFR T790M Mutation-Positive NCSLC Personalised medicine - Lung and other thoracic tumours - Anticancer agents & Biologic therapy
28 Oct 2016 Media Alert: ESMO Symposium on Immuno-Oncology 2016 Cancer Immunology and Immunotherapy
28 Oct 2016 FDA Approves Pembrolizumab for First-Line Treatment of Metastatic NSCLC Lung and other thoracic tumours - Cancer Immunology and Immunotherapy
27 Oct 2016 EMA Recommends a Change to the Terms of the Marketing Authorisation for Arsenic Trioxide Haematologic malignancies - Anticancer agents & Biologic therapy
03 Nov 2016 Now Available in Russian, the ESMO/ACF Patient Guide on Pancreatic Cancer
26 Oct 2016 Off-Label Drug Coverage in Oncology Bioethics, legal and economic issues - Anticancer agents & Biologic therapy
24 Oct 2016 FDA Grants Accelerated Approval to New Treatment for Advanced STS Sarcomas - Anticancer agents & Biologic therapy
24 Oct 2016 FDA Modifies Indication for Erlotinib in NSCLC Lung and other thoracic tumours - Anticancer agents & Biologic therapy
21 Oct 2016 2016 Nobel Prize in Physiology or Medicine Basic science
20 Oct 2016 FDA Approves Atezolizumab for Metastatic NSCLC Lung and other thoracic tumours - Cancer Immunology and Immunotherapy
19 Oct 2016 EMA Adopts a New Indication for Nivolumab Haematologic malignancies - Cancer Immunology and Immunotherapy